Non-invasive tests significantly predicted liver-related deaths

during follow up in patients without SVR. Compared to low APRI, the increased risk for liver death was 2.672 (95% CI 0.617-11.568) p=.189 for Int APRI, and 8.377 (95% CI 2.000-35.080) p=.004 for High APRI. Compared to low FIB-4, the risk for liver death was 4.151 (95% CI 1.222-14.100) p=0.023 for Int FIB-4, and 10.824 (95% CI 3.293-35.584) p<.0001 for High FIB-4. Kaplan Meier curves of time Lenvatinib to liver death are similar for Low and Int groups through 4 years, and then begin to diverge with increasing deaths in the Int group. CONCLUSION: Both APRI and FIB-4 predict risk for liver death and liver events over time. High risk categories identify patients with high short term risks and should be given priority for immediate treatment. Int risk categories have find more a high prevalence of advanced fibrosis and a 20% risk of liver death, but the risk of death compared with the Low group is not increased until 4 years of follow-up. Conversely, use of cutoff values for Low risk of fibrosis will miss relatively few liver-related

deaths over ten years. These data support a sequential targeting of HCV patients according to non-invasive fibrosis category over the near term in order to optimize available resources and outcomes. Disclosures: Samuel B. Ho – Grant/Research Support: Roche, Genentech, Vital Therapies, Aspire Bariatrics, Gilead Erik J. Groessl – Stock Shareholder: Bristol Myers Ribonucleotide reductase Squibb The following people have nothing to disclose: Paul Thuras, Eric Dieperink Background Recent studies show that at least 2 per 1000 people in the greater Dublin area have been diagnosed with HIV infection. Prevalence rates for Hepatitis C (HCV) in Ireland have varied in previous studies from 0.5-1.2%. True Hepatitis B (HBV) prevalence rate in Ireland is unknown. Given the recent improvement in treatment options for HIV and Hepatitis C (HCV) and sustained late presentation of new HIV diagnoses, Emergency Medicine, Infectious Diseases, Hepatology and Laboratory Medicine collaboratively proposed a universal screening scheme as a pilot study. Methods An opt-out screening programme for Blood

Borne Viruses (BBV) including HIV antibody, Hepatitis B surface antigen and Hepatitis C antibody was introduced in March 2014 in our Emergency Department. Following appropriate ethical approval, all patients undergoing blood sampling in the department as part of routine clinical care were offered serological testing for the above viral panel. A primary aim of our study is to assess feasibility and acceptability of this screening approach. A secondary aim is to describe prevalence rates of both new and known HIV, HBV and HCV infection. Targets for uptake of BBV panel in those who had bloods drawn were set at 50% for month 1 and 2 and 80% for month 3 onwards. Results Over the first 10 weeks of testing, 2359 samples were obtained with results of the first 2059 samples presented.